Dabigatran, a new direct thrombin inhibitor, achieves strong anticoagulation that is more
predictable than warfarin. Nevertheless, a patient on dabigatran therapy (DT) may suffer …

Background In clinical practice, physicians are given the choice of selecting one of two
dabigatran doses based on patient characteristics, with the lower dose typically used in …

Background Activated partial thromboplastin time (aPTT) is recommended for monitoring
anticoagulant activity in dabigatran-treated patients; however, there are limited data in …

The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring,
however emergency measurements are gaining importance. Current assays feature good …

Dabigatran etexilate is an oral direct thrombin inhibitor used in preventing thromboembolism
in patients with atrial fibrillation and several other conditions. Routine dabigatran …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Dabigatran is an oral anticoagulant that is increasingly used for atrial fibrillation (AF).
Presently, many authorities state that routine laboratory coagulation monitoring is not …

Special circumstances may require the measurement of the anticoagulant effect of
dabigatran etexilate. No data currently link any given coagulation test to bleeding outcomes …

Background: Few data exist regarding frequency and predictors of bleeding complications
associated with anticoagulant therapy using dabigatran in Japanese patients with atrial …

Background Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of
stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran …